Physician profile
Billy Manuel
NPI 1093293383
$6,578.33
in general payments reported to CMS, 2019-2025
20 companies · $1,894 in 2025
The $1,894 reported for 2025 was more than what 91% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,393 · 2022: $964 · 2023: $1,115 · 2024: $1,212 · 2025: $1,894.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,221.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,221.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,455.34 | 2021-2025 | Caplyta |
| Abbvie INC. | $790.30 | 2021-2025 | |
| Indivior INC. | $693.07 | 2021-2025 | Perseris, Sublocade |
| Alkermes, INC. | $638.23 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Teva Pharmaceuticals USA, INC. | $629.64 | 2021-2025 | Uzedy, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $582.12 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Neurocrine Biosciences, INC. | $386.03 | 2023-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $372.94 | 2021-2025 | Spravato, Invega Sustenna, Invega |
| Lundbeck LLC | $336.90 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $150.17 | 2024-2025 | Auvelity |
| Avanir Pharmaceuticals, INC. | $110.44 | 2022 | |
| Vanda Pharmaceuticals INC. | $103.02 | 2025 | Fanapt, Hetlioz |
| Sunovion Pharmaceuticals INC. | $99.71 | 2021-2022 | |
| Gilead Sciences, INC. | $63.01 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $54.45 | 2021-2024 | Trintellix |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $39.48 | 2021-2022 | |
| Hikma Pharmaceuticals USA | $20.81 | 2021 | |
| Neos Therapeutics, LP | $20.05 | 2025 | Exxua |
| Bioxcel Therapeutics, INC. | $19.70 | 2023 | Igalmi |
| Neuronetics, INC. | $12.92 | 2023 | Neurostar Tms Therapy System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Billy Manuel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.